bro β-Lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 91-97

  Khan, Mushtaq A ^a   Northwood, John Blackman ^b   Levy, Foster ^c   Verhaegh, Suzanne J C ^a   Farrell, David J ^b   van Belkum, Alex ^a   Hays, John P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Quotient Bioresearch Ltd   (United Kingdom)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Ampicillin; Antibiotic susceptibility; Demographic distribution; Geographic distribution

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE BRO 1; BETA LACTAMASE BRO 2; CEFACLOR; CEFPODOXIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL DNA; BRO BETA LACTAMASE; BRO BETA-LACTAMASE;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; GEOGRAPHIC DISTRIBUTION; HETEROZYGOTE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRESCHOOL CHILD; BIOSYNTHESIS; CLASSIFICATION; DNA FINGERPRINTING; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MORAXELLACEAE INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DNA FINGERPRINTING; DNA, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 77950343888     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp401     Document Type: Article

References (32)

1. Verduin CM, Hol C, Fleer A et al. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002; 15: 125-44.
2. Hays JP. The genus Moraxella. In: Dworkin M, Falkow S, Rosenberg E et al., eds. The Prokaryotes. 3rd edn. New York: Springer, 2006; 958-87.
3. Wallace RJ Jr, Steingrube VA, Nash DR et al. BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother 1989; 33: 1845-54.
4. Verhaegh SJ, Streefland A, Dewnarain JK et al. Age-related genotypic and phenotypic differences in Moraxella catarrhalis isolates from children and adults presenting with respiratory disease in 2001-2002. Microbiology 2008; 154: 1178-84.
5. Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother 1977; 3: 374-5.
6. Fritsche TR, Sader HS, Stilwell MG et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005; 52: 187-93.
7. Johnson DM, Sader HS, Fritsche TR et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 47: 373-6.
8. Deshpande LM, Sader HS, Fritsche TR et al. Contemporary prevalence of BRO β-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J Clin Microbiol 2006; 44: 3775-7.
9. Morrissey I, Maher K, Williams L et al. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007. J Antimicrob Chemother 2008; 62 Suppl 2: ii97-103.
10. Eliasson I, Kamme C, Vang M et al. Characterization of cell-bound papain-soluble β-lactamases in BRO-1 and BRO-2 producing strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens. Eur J Clin Microbiol Infect Dis 1992; 11: 313-21.
11. Bootsma HJ, van Dijk H, Verhoef J et al. Molecular characterization of the BRO β-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 1996; 40: 966-72.
12. Bootsma HJ, Aerts PC, Posthuma G et al. Moraxella (Branhamella) catarrhalis BRO β-lactamase: a lipoprotein of gram-positive origin? J Bacteriol 1999; 181: 5090-3.
13. Bootsma HJ, van Dijk H, Vauterin P et al. Genesis of BRO β-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000; 36: 93-104.
14. Levy F, Walker ES. BRO β-lactamase alleles, antibiotic resistance and a test of the BRO-1 selective replacement hypothesis in Moraxella catarrhalis. J Antimicrob Chemother 2004; 53: 371-4.
15. Hol C, Van Dijke EE, Verduin CM et al. Experimental evidence for Moraxella-induced penicillin neutralization in pneumococcal pneumonia. J Infect Dis 1994; 170: 1613-6.
16. Wardle JK. Branhamella catarrhalis as an indirect pathogen. Drugs 1986; 31 Suppl 3: 93-6.
17. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 Suppl S1: 1-7.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 2000.
19. Yokota S, Harimaya A, Sato K et al. Colonization and turnover of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in otitis-prone children. Microbiol Immunol 2007; 51: 223-30.
20. Inoue M, Kaneko K, Akizawa K et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-3 (1999-2002). J Infect Chemother 2006; 12: 9-21.
21. Canton R. Resistance trends in Moraxella catarrhalis (PROTEKT years 1-3 [1999-2002]). J Chemother 2004; 16 Suppl 6: 63-70.
22. Berk SL, Kalbfleisch JH. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. The Alexander Project Collaborative Group. J Antimicrob Chemother 1996; 38 Suppl A: 85-96.
23. Esel D, Ay-Altintop Y, Yagmur G et al. Evaluation of susceptibility patterns and BRO β-lactamase types among clinical isolates of Moraxella catarrhalis. Clin Microbiol Infect 2007; 13: 1023-5.
24. Jetter M, Heiniger N, Spaniol V et al. Outer membrane porin M35 of Moraxella catarrhalis mediates susceptibility to aminopenicillins. BMC Microbiol 2009; 9: 188.
25. Kadry AA, Fouda SI, Elkhizzi NA et al. Correlation between susceptibility and BRO type enzyme of Moraxella catarrhalis strains. Int J Antimicrob Agents 2003; 22: 532-6.
26. Walker ES, Neal CL, Laffan E et al. Long-term trends in susceptibility of Moraxella catarrhalis: a population analysis. J Antimicrob Chemother 2000; 45: 175-82.
27. Reinert RR, Rodloff AC, Halle E et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: results from the PROTEKT surveillance study (1999-2000). Chemotherapy 2004; 50: 143-51.
28. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
29. Mendes C, Marin ME, Quinones F et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000). Braz J Infect Dis 2003; 7: 44-61.
30. McGregor K, Chang BJ, Mee BJ et al. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO β-lactamases. Eur J Clin Microbiol Infect Dis 1998; 17: 219-34.
31. Wong DM, Blumberg DA, Lowe LG. Guidelines for the use of antibiotics in acute upper respiratory tract infections. Am Fam Physician 2006; 74: 956-66.
32. Baba H, Inoue M, Farrell DJ. Increasing prevalence of β-lactam resistant Haemophilus influenza in Japan: in vitro activity of telithromycin and β-lactam antimicrobials over 4 years. In: Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 2005. Abstract 1134_04_123. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.